Skip to main content
Top
Published in: Head & Neck Oncology 1/2011

Open Access 01-12-2011 | Review

How to do it: the difficult thyroid

Authors: Tahwinder Upile, Waseem Jerjes, Jaspal Mahil, Hitesh Tailor, Ramkishan Balakumar, Anuja Rao, Yassar Qureshi, Iain Bowman, Suchana Mukhopadhyay

Published in: Head & Neck Oncology | Issue 1/2011

Login to get access

Abstract

There is a paucity of publications detailing how to deal with the difficult thyroid cancer. When compared to other cancers, it is relatively rare with several histopathological subtypes which run differing clinical courses and respond to different therapies. It is a condition predominately treated by specifically trained General and now ENT surgeons who already have a thorough knowledge of vocal fold assessment and rehabilitation as well as emergency airways management both to avoid and treat common complications should they occur.
Good surgery involves a team effort to produce good results consistently. All members of the team are essential to quality service delivery. Communication with the team and the patient is paramount. We describe our approach to the difficult thyroid.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yip L, Stang MT, Carty SE: Thyroid carcinoma: the surgeon's perspective. Radiol Clin North Am. 2011, 49 (3): 463-71. 10.1016/j.rcl.2011.02.007. viCrossRefPubMed Yip L, Stang MT, Carty SE: Thyroid carcinoma: the surgeon's perspective. Radiol Clin North Am. 2011, 49 (3): 463-71. 10.1016/j.rcl.2011.02.007. viCrossRefPubMed
2.
go back to reference Upile T, Jerjes W, Nouraei SA, Singh S, Clarke P, Rhys-Evans P, Hopper C, Howard D, Wright A, Sudhoff H, Fisher C, Sandison A: How we do it: a method of neck dissection for histopathological analysis. BMC Surg. 2007, 7: 21-10.1186/1471-2482-7-21.PubMedCentralCrossRefPubMed Upile T, Jerjes W, Nouraei SA, Singh S, Clarke P, Rhys-Evans P, Hopper C, Howard D, Wright A, Sudhoff H, Fisher C, Sandison A: How we do it: a method of neck dissection for histopathological analysis. BMC Surg. 2007, 7: 21-10.1186/1471-2482-7-21.PubMedCentralCrossRefPubMed
3.
go back to reference Hanley JA, Lippman-Hand A: If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA. 1983, 249 (13): 1743-5. 10.1001/jama.1983.03330370053031.CrossRefPubMed Hanley JA, Lippman-Hand A: If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA. 1983, 249 (13): 1743-5. 10.1001/jama.1983.03330370053031.CrossRefPubMed
4.
go back to reference Eypasch E, Lefering R, Kum CK, Troidl H: Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995, 311 (7005): 619-20. 10.1136/bmj.311.7005.619.PubMedCentralCrossRefPubMed Eypasch E, Lefering R, Kum CK, Troidl H: Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995, 311 (7005): 619-20. 10.1136/bmj.311.7005.619.PubMedCentralCrossRefPubMed
Metadata
Title
How to do it: the difficult thyroid
Authors
Tahwinder Upile
Waseem Jerjes
Jaspal Mahil
Hitesh Tailor
Ramkishan Balakumar
Anuja Rao
Yassar Qureshi
Iain Bowman
Suchana Mukhopadhyay
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Head & Neck Oncology / Issue 1/2011
Electronic ISSN: 1758-3284
DOI
https://doi.org/10.1186/1758-3284-3-54

Other articles of this Issue 1/2011

Head & Neck Oncology 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine